← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rxbio, Inc.
Johnson City, TN
$14,849,571
Total funding
11
Grants
Funding over time
peak $2.5M · FY2007–20$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$13,066,441 · 9
DOD$1,783,130 · 2
By mechanism
N01$11,171,451 · 2
—$1,783,130 · 2
RC1$731,010 · 1
R43$717,055 · 4
R41$252,128 · 1
N43$194,797 · 1
Investigators at Rxbio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$1,999,315
N01 · FY2013 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$1,998,947
N01 · FY2014 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$1,998,223
N01 · FY2015 · AI
IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.$1,529,303
N01 · FY2019 · AI
IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.$1,524,658
N01 · FY2020 · AI
IND-Enabling Development of Rx100 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome.$1,519,121
N01 · FY2018 · AI
RX 100: IN VITRO MECHANISM OF ACTION AND PRECLINICAL PHARMOCOKINETIC$1,049,055
· FY2012 · Department of the Army
NON TOXIC INSECT RESISTANT TEXTILES FOR MILITARY CLOTHING$734,075
· FY2012 · Department of Defense
Radioprotective / Radiomitigating Efficacy of Rx100 in the Gastrointestinal Tract$499,999
RC1 · FY2007 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$396,356
N01 · FY2018 · AI
Development of Rx100 as Novel Medical Countermeasure for Acute Radiation Syndrome$297,087
R43 · FY2015 · AI
Targeted Therapies for the Treatment of GI-ARS Diarrhea$252,128
R41 · FY2020 · DK
Radioprotective / Radiomitigating Efficacy of Rx100 in the Gastrointestinal Tract$231,011
RC1 · FY2009 · AI
The anti-diarrheal potential of a LPA analog Rx100$222,829
R43 · FY2015 · DK
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$205,528
N01 · FY2017 · AI
TAS::75 0849::TAS$194,797
N43 · FY2011 · CA
Development of an LPA receptor modulator Rx100 as a radioprotectant$99,977
R43 · FY2008 · CA
LPA Receptor Modulators as Radioprotectants$97,162
R43 · FY2007 · CA